Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients

Inge K Holden; Claus Bistrup; Anna Christine Nilsson; Janne Fuglsang Hansen; Rozeta Abazi; Jesper Rømhild Davidsen; Mikael Kjaer Poulsen; Susan Olaf Lindvig; Ulrik S Justesen; Isik Somuncu Johansen

doi:10.1111/joim.13361

Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients

Inge K Holden, Claus Bistrup, Anna Christine Nilsson, Janne Fuglsang Hansen, Rozeta Abazi, Jesper Rømhild Davidsen, Mikael Kjaer Poulsen, Susan Olaf Lindvig, Ulrik S Justesen, Isik Somuncu Johansen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

46 Downloads (Pure)

Abstract

Background: It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. Results: A total of 80 SOT recipients completed a two-dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine. Conclusion: This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination.

Originalsprog	Engelsk
Tidsskrift	Journal of Internal Medicine
Vol/bind	290
Udgave nummer	6
Sider (fra-til)	1264-1267
ISSN	0954-6820
DOI	https://doi.org/10.1111/joim.13361
Status	Udgivet - dec. 2021

Bibliografisk note

Dokumenter og links

10.1111/joim.13361Licens: CC BY-NC-ND

Open Access VersionForlagets udgivne version, 273 KBLicens: CC BY-NC-ND

Citationsformater

@article{65d4ed65f0724fd19f8f334b594f978e,

title = "Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients",

abstract = "Background: It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. Results: A total of 80 SOT recipients completed a two-dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine. Conclusion: This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination.",

keywords = "Covid-19, immune response, solid organ transplant recipient, vaccine",

author = "Holden, {Inge K} and Claus Bistrup and Nilsson, {Anna Christine} and Hansen, {Janne Fuglsang} and Rozeta Abazi and Davidsen, {Jesper R{\o}mhild} and Poulsen, {Mikael Kjaer} and Lindvig, {Susan Olaf} and Justesen, {Ulrik S} and Johansen, {Isik Somuncu}",

year = "2021",

month = dec,

doi = "10.1111/joim.13361",

language = "English",

volume = "290",

pages = "1264--1267",

journal = "Journal of Internal Medicine",

issn = "0954-6820",

publisher = "Wiley",

number = "6",

}

TY - JOUR

T1 - Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients

AU - Holden, Inge K

AU - Bistrup, Claus

AU - Nilsson, Anna Christine

AU - Hansen, Janne Fuglsang

AU - Abazi, Rozeta

AU - Davidsen, Jesper Rømhild

AU - Poulsen, Mikael Kjaer

AU - Lindvig, Susan Olaf

AU - Justesen, Ulrik S

AU - Johansen, Isik Somuncu

PY - 2021/12

Y1 - 2021/12

N2 - Background: It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. Results: A total of 80 SOT recipients completed a two-dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine. Conclusion: This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination.

AB - Background: It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. Results: A total of 80 SOT recipients completed a two-dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine. Conclusion: This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination.

KW - Covid-19

KW - immune response

KW - solid organ transplant recipient

KW - vaccine

U2 - 10.1111/joim.13361

DO - 10.1111/joim.13361

M3 - Journal article

C2 - 34237179

SN - 0954-6820

VL - 290

SP - 1264

EP - 1267

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

IS - 6

ER -

Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients

Abstract

Bibliografisk note

Dokumenter og links

Fingeraftryk

Citationsformater